Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Stock Report

Market Cap: US$2.6b

Supernus Pharmaceuticals Valuation

Is SUPN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SUPN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$217.63
Fair Value
78.9% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: SUPN ($46.02) is trading below our estimate of fair value ($217.63)

Significantly Below Fair Value: SUPN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SUPN?

Key metric: As SUPN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SUPN. This is calculated by dividing SUPN's market cap by their current revenue.
What is SUPN's PS Ratio?
PS Ratio3.9x
SalesUS$681.54m
Market CapUS$2.64b

Price to Sales Ratio vs Peers

How does SUPN's PS Ratio compare to its peers?

The above table shows the PS ratio for SUPN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.2x
PBH Prestige Consumer Healthcare
2.6x1.69%US$2.9b
BHC Bausch Health Companies
0.2x-1.68%US$2.5b
OCUL Ocular Therapeutix
41.4x51.70%US$2.3b
PRGO Perrigo
0.5x0.75%US$2.0b
SUPN Supernus Pharmaceuticals
3.9x15.31%US$2.6b

Price-To-Sales vs Peers: SUPN is good value based on its Price-To-Sales Ratio (3.9x) compared to the peer average (11.2x).

Price to Sales Ratio vs Industry

How does SUPN's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

68 CompaniesPrice / SalesEstimated GrowthMarket Cap
VTRS Viatris
0.8x1.65%US$11.66b
AMRX Amneal Pharmaceuticals
1.2x7.49%US$3.57b
BHC Bausch Health Companies
0.2x-1.68%US$2.46b
PRGO Perrigo
0.5x0.75%US$1.99b
SUPN 3.9xIndustry Avg. 4.0xNo. of Companies68PS0612182430+
68 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SUPN is good value based on its Price-To-Sales Ratio (3.9x) compared to the US Pharmaceuticals industry average (4x).

Price to Sales Ratio vs Fair Ratio

What is SUPN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SUPN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.9x
Fair PS Ratio6.9x

Price-To-Sales vs Fair Ratio: SUPN is good value based on its Price-To-Sales Ratio (3.9x) compared to the estimated Fair Price-To-Sales Ratio (6.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SUPN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$46.02
US$59.33
+28.93%
12.79%US$65.00US$43.00n/a6
Nov ’26US$55.13
US$59.33
+7.62%
12.79%US$65.00US$43.00n/a6
Oct ’26US$48.04
US$49.20
+2.41%
17.36%US$63.00US$40.00n/a5
Sep ’26US$45.12
US$43.80
-2.93%
4.88%US$46.00US$40.00n/a5
Aug ’26US$35.51
US$40.20
+13.22%
7.77%US$45.00US$36.00n/a5
Jul ’26US$31.82
US$39.00
+22.56%
8.58%US$45.00US$36.00n/a5
Jun ’26US$31.70
US$38.80
+22.40%
7.71%US$44.00US$36.00n/a5
May ’26US$32.45
US$38.80
+19.57%
7.71%US$44.00US$36.00n/a5
Apr ’26US$31.68
US$38.80
+22.47%
7.71%US$44.00US$36.00n/a5
Mar ’26US$32.06
US$38.80
+21.02%
7.71%US$44.00US$36.00n/a5
Feb ’26US$38.37
US$42.80
+11.55%
17.45%US$57.00US$36.00n/a5
Jan ’26US$36.16
US$39.25
+8.55%
6.59%US$43.00US$36.00n/a4
Dec ’25US$36.57
US$39.25
+7.33%
6.59%US$43.00US$36.00n/a4
Nov ’25US$33.97
US$39.25
+15.54%
6.59%US$43.00US$36.00US$55.134
Oct ’25US$32.00
US$39.25
+22.66%
6.59%US$43.00US$36.00US$48.044
Sep ’25US$35.16
US$40.50
+15.19%
4.45%US$43.00US$38.00US$45.124
Aug ’25US$29.57
US$40.50
+36.96%
4.45%US$43.00US$38.00US$35.514
Jul ’25US$26.55
US$40.50
+52.54%
4.45%US$43.00US$38.00US$31.824
Jun ’25US$27.12
US$40.50
+49.34%
4.45%US$43.00US$38.00US$31.704
May ’25US$30.08
US$40.50
+34.64%
4.45%US$43.00US$38.00US$32.454
Apr ’25US$33.52
US$40.50
+20.82%
4.45%US$43.00US$38.00US$31.684
Mar ’25US$31.01
US$40.50
+30.60%
4.45%US$43.00US$38.00US$32.064
Feb ’25US$27.86
US$41.00
+47.16%
5.17%US$43.00US$38.00US$38.374
Jan ’25US$28.94
US$41.00
+41.67%
5.17%US$43.00US$38.00US$36.164
Dec ’24US$27.58
US$41.00
+48.66%
5.17%US$43.00US$38.00US$36.574
Nov ’24US$23.91
US$40.75
+70.43%
4.71%US$43.00US$38.00US$33.974
US$59.33
Fair Value
22.4% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/10 09:22
End of Day Share Price 2025/11/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarBerenberg
Pavan PatelBofA Global Research
David BuckB. Riley Securities, Inc.